Interestingly, SPARC overexpression by tumor-associated fibroblasts in pancreatic and lung cancer is also a marker of bad prognosis despite the fact that the malignant cells themselves are SPARC-negative due to promoter hypermethylation [33], [50]. This evidence concerns the gene SPARC and lung carcinoma.